Literature DB >> 712636

The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man.

R D Miller, S Agoston, L H Booij, U W Kersten, J F Crul, J Ham.   

Abstract

To determine the potency of pancuronium and its metabolites, 3-OH-, 17-OH- and 3,17-OH-pancuronium, cumulative dose-response curves were determined in five anesthetized patients with each drug. Pancuronium (ED50 = 0.041 mg/kg) was 2 times more potent than 3-OH-pancuronium (ED50 = 0.082 mg/kg), 50 times more potent than 17-OH-pancuronium (ED50 = 2.0 mg/kg) and 54 times more potent than 3,17-OH--pancuronium (ED50 = 2.15 mg/kg). In 21 other patients, one equipotent dose of either pancuronium or one of its metabolites was given as an i.v. bolus. Onset time and duration of neuromuscular blockade from 3-OH- and 3,17-OH-pancuronium did not differ significantly from that of pancuronium; 17-OH-pancuronium had a shorter duration of action than did pancuronium. Although pancuronium tended to have a slightly longer elimination half-life, the pharmacokinetics of the four drugs did not differ significantly. The elimination half-lifes were 110, 68, 73 and 71 min for pancuronium and its 3-OH, 17-OH and 3,17-OH derivatives, respectively. We conclude that although pancuronium is more potent than its 3-OH, 17-OH and 3,17-OH metabolites, the pharmacokinetics of these three metabolites do not differ from each other and from that of pancuronium.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 712636

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Recent developments with muscles relaxants and their antagonists.

Authors:  R D Miller
Journal:  Can Anaesth Soc J       Date:  1979-03

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  J Clin Monit       Date:  1990-01

4.  Toxic adenoma of the thyroid gland and Wolff-Parkinson-White syndrome.

Authors:  M Naço; E Celiku; A Llukaçaj; J Shehaj; R Kameniku
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 5.  Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations.

Authors:  D K Meijer; W E Mol; M Müller; G Kurz
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

6.  Atracurium, pharmacokinetics and metabolites.

Authors:  F Donati
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 7.  Org-NC45: a new steroidal non-depolarizing muscle relaxant.

Authors:  L H Booij; T B Vree; J E Crul
Journal:  Pharm Weekbl Sci       Date:  1982-02-19

Review 8.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

9.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

10.  Pharmacokinetic and pharmacodynamic modelling with pancuronium.

Authors:  M A Evans; C A Shanks; K F Brown; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.